| Objective To investigate the effect of Valsartan on decreasing proteinuria and serum transforming growth factor beta(TGF-β1) levels in the treated patients with chronic glomerulonephritis.Methods 35 patients with chronic glomerulonephritis were included in this study, treated with the immunosuppresants for one or over one course and the proteinuria was not decreased. All patients received the combined treatment with Valsartan(80mg/d) for 12 weeks on the base of previous treatment. Blood pressure, 24hours urinary protein excretion, serum TGF-β1, liver function,renal function and hemoglobin weredetermined at baseline and after 12 weeks treatment period.Results After 12 weeks of valsartan therapy, 24hours urinary protein excretion decreased from 1.92 ± 0. 52g to 1.51±0.51g(n=35), decreased 22% (p<0. 01) , serum TGF-β1 decreased from 57. 32 + 11. 73pg/ml to 45.28 ± 9.02pg/ml, decreased 21% ( p<0.01 ) .No obvious alteration could be found in blood pressure, liver function, renal function and hemoglobin after the treatment of valsartan.Conclusion Valsartan decreases urinary protein excretion in patients with chronic glomerulonephritis. Its antiproteinuria effect is probably independent of its hypotensive effect and might be concerned with the decrease of TGF-β1.
|
PDF Full Text Request